BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

In This Article: On Friday, BofA increased its price target for Merus (NASDAQ:MRUS) to $92 from $70, while maintaining a Buy rating on the stock. The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and…